In "Episode 2" of the series on "Present and future of diagnostics in prostate cancer," Prof. Monique Roobol (NL) and Dr. Tamás Fazekas (HU) review the ongoing debate surrounding prostate cancer screening.

They review the history and development of screening strategies, including the key findings from early trials and the progression toward more personalised, risk-stratified approaches.

Prof. Roobol discusses the significance of PSA testing and how it serves as a tool for initial risk stratification, while also addressing the role of advanced techniques like MRI and novel biomarkers in improving screening accuracy. The episode also highlights the need to balance the benefits of early detection with the risks of overdiagnosis, and the speakers share their insights into how the latest clinical trials are shaping the future of prostate cancer screening.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.